To date, carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and p53, which are now clinically used as ESCC tumor markers, are inadequate for identifying subclinical patients with early tumors and predicting disease recurrence [6]. This evidence concerns the gene CEACAM5 and esophageal squamous cell carcinoma.